Programs

Clinical Trials

Firmonertinib

ArriVent is studying firmonertinib (previously furmonertinib) globally in patients with NSCLC with EGFR exon 20 insertion mutations and EGFR P-Loop and Alpha C-Helix Compressing (PACC) Uncommon Mutations. To learn more about these clinical studies, please select from below or visit clinicaltrials.gov.

FURTHER (FURMO-002)

Study of Firmonertinib in Patients with Advanced or Metastatic Non-Small Cell Lung Cancer With Activating EGFR including PACC Mutations (NCT05364073)

Learn more at clinicaltrials.gov/study/NCT05364073

FURVENT (FURMO-004)

First-line Study to Compare Firmonertinib to Platinum-Based Chemotherapy for Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations (NCT05607550)

Learn more at clinicaltrials.gov/study/NCT05607550

ALPACCA (FURMO-006)

Study to Evaluate Efficacy and Safety of Firmonertinib Compared With Investigator’s Choice of EGFR Inhibitor as First-Line Treatment in Participants Who Have Locally Advanced or Metastatic NSCLC With EGFR P-Loop and Alpha C-Helix Compressing (PACC) Uncommon Mutations (NCT07185997)

Learn more at clinicaltrials.gov/study/NCT07185997

SHP2 Combination Trial

Study of Furmonertinib in combination with ICP-189, a SHP2 (SHP2i), in collaboration with Beijing InnoCare Pharma Tech Co., Ltd., in classical EGFRm Non-Small Cell Lung Cancer Patients

For more information about firmonertinib clinical studies:

800-583-7566 FURMO@arrivent.com